[Correspondence] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer

We read with great interest the ADJUVANT study,1 the first prospective phase 3 study showing longer disease-free survival for adjuvant tyrosine-kinase inhibitor (TKI) treatment than for cisplatin-based chemotherapy in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer (NSCLC). However, some important issues remain.

http://ift.tt/2GO5OXh